Relationship Between Changes in Serum Levels of Intact Parathyroid Hormone and Sclerostin After a Single Dose of Zoledronic Acid: Results of a Phase 1 Pharmacokinetic Study
Although changes in serum sclerostin levels at 12 months after infusion of zoledronic acid have been reported, the changes in sclerostin levels at earlier time points are poorly understood. We reanalyzed the study data of a previous phase 1 pharmacokinetic study and investigated the correlation between changes in sclerostin levels and relevant factors in calcium metabolism. A total of 24 Japanese female subjects with primary postmenopausal osteoporosis were administered a single 4- or 5-mg dose of zoledronic acid. Serum and urine samples were collected on days 15, 29, 90, 180, and 365 after administration. Serum levels of calcium, phosphate, intact parathyroid hormone (iPTH), and sclerostin were measured. Levels of serum sclerostin were unchanged from baseline on days 15 and 29, but increased significantly on day 90, subsequently decreased significantly on day 180, and returned to baseline levels on day 365. A significant negative correlation was observed between changes in iPTH levels at early time points and sclerostin levels at later time points. This suggests that sclerostin was negatively regulated by iPTH, and the decrease in sclerostin may indicate the start of bone formation during later time points after zoledronic acid injection.
Kuroda, Tatsuhiko, Shiraki, Masataka, Nakamura, Toshitaka et al. Relationship Between Changes in Serum Levels of Intact Parathyroid Hormone and Sclerostin After a Single Dose of Zoledronic Acid: Results of a Phase 1 Pharmacokinetic Study. // Calcified Tissue International. – 2022. – DOI: 10.1007/s00223-021-00900-w. – URL: http://link.springer.com/openurl/fulltext?id=doi:10.1007/s00223-021-00900-w
Kuroda, Tatsuhiko, Shiraki, Masataka, Nakamura, Toshitaka, Suzuki, Hiroaki, Hiraishi, Kazuki, Sugimoto, Toshitsugu, Tanaka, & Satoshi (2022). Relationship Between Changes in Serum Levels of Intact Parathyroid Hormone and Sclerostin After a Single Dose of Zoledronic Acid: Results of a Phase 1 Pharmacokinetic Study. Calcified Tissue International. https://doi.org/10.1007/s00223-021-00900-w
Kuroda, et al. “Relationship Between Changes in Serum Levels of Intact Parathyroid Hormone and Sclerostin After a Single Dose of Zoledronic Acid: Results of a Phase 1 Pharmacokinetic Study.” Calcified Tissue International, 2022. doi:10.1007/s00223-021-00900-w.
@article{Kuroda2022,
title = {Relationship Between Changes in Serum Levels of Intact Parathyroid Hormone and Sclerostin After a Single Dose of Zoledronic Acid: Results of a Phase 1 Pharmacokinetic Study},
author = {Kuroda and Tatsuhiko and Shiraki and Masataka and Nakamura and Toshitaka and Suzuki and Hiroaki and Hiraishi and Kazuki and Sugimoto and Toshitsugu and Tanaka and Satoshi},
journal = {Calcified Tissue International},
year = {2022},
doi = {10.1007/s00223-021-00900-w},
url = {http://link.springer.com/openurl/fulltext?id=doi:10.1007/s00223-021-00900-w}
}
The human microbiota functions at the interface between diet, medication-use, lifestyle, host immune development and health. It is therefore closely aligned with many of the recognised modifiable factors that influence bone mass accrual...
Mazabraud’s syndrome (MZB) is a rare condition in which fibrous dysplasia of bone/the McCune-Albright syndrome (FD/MAS) co-exists with intramuscular myxomas. Both FD and the myxomas harbor the GNAS- mutation. Recent studies have shown...
Trans-sutural distraction osteogenesis has been proposed as an alternative technique of craniofacial remodelling surgery for craniosynostosis correction. Many studies have defined the contribution of a series of biological events to...
Pseudoachondroplasia (PSACH) and multiple epiphyseal dysplasia type 1 (MED1) are two rare skeletal disorders caused by cartilage oligomeric matrix protein ( COMP ) variants. This study aims to analyze the genotype and phenotype of...
Patients with Osteogenesis Imperfecta (OI) present extra-skeletal manifestations, including important orodental and craniofacial features as dentinogenesis imperfecta, dental agenesis, failure of maxilla growth and hypotonia of...